Schmid J, Bücheler A, Müller B
Department of Pharmacokinetics and Drug Metabolism, Dr. Karl Thomae GmbH, Biberach, Germany.
J Chromatogr B Biomed Appl. 1994 Aug 5;658(1):93-101. doi: 10.1016/0378-4347(94)00199-5.
A method has been developed for the measurement of zatebradine (UL-FS 49), a heart-rate lowering drug, suitable for the treatment of stable angina pectoris. The method comprises a fully automated liquid-solid extraction using a Zymark Benchmate, a capillary gas chromatography and ammonia chemical ionisation (CI) mass spectrometry using hexadeuterated zatebradine for the internal standard. The assay has a mean between-batch imprecision of 4.9% and a mean inaccuracy of 1.5%. The calibration curve covers the range of 1-30 ng/ml. About 60 samples can be handled per day. The assay has been successfully applied to human pharmacokinetic studies.
已开发出一种用于测定扎替雷定（UL-FS 49）的方法，扎替雷定是一种可降低心率的药物，适用于治疗稳定型心绞痛。该方法包括使用Zymark Benchmate全自动液固萃取、毛细管气相色谱法以及使用十六氘代扎替雷定作为内标的氨化学电离（CI）质谱法。该测定法的批间平均不精密度为4.9%，平均误差为1.5%。校准曲线覆盖1 - 30 ng/ml的范围。每天大约可处理60个样本。该测定法已成功应用于人体药代动力学研究。
